ALKS Earnings Prediction
The chart below shows how ALKS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, ALKS sees a -1.83% change in stock price 10 days leading up to the earnings, and a +0.03% change 10 days following the report. On the earnings day itself, the stock moves by +0.97%. This data can give you a slight idea of what to expect for the next quarter's release.
ALKS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
378.14M
-0.73%
-5.26%
Gross Margin
83.31%
2.23%
-1.52%
Operating Margin
27.70%
111.61%
0.62%
Net Margin
24.54%
95.69%
3.46%
EPS
0.55
96.43%
3.77%
No Data Available
ALKS Earnings Analysis
Alkermes Inc. plc Corporation (ALKS.O) Earnings Conference Call
Positive
Net Sales Growth: During the third quarter, our teams drove aggregate net sales of $273 million reflecting 18% year-over-year growth.
Proprietary Net Sales Target: We’re on track to achieve our previously announced financial expectations of proprietary net sales in excess of $1 billion in 2024.
Strong Sales Growth: Net sales in the third quarter were $113.7 million representing strong year-over-year growth of 14%, driven by underlying demand and growth in alcohol dependence indications.
VIVITROL Sales Forecast: For the full year, we expect VIVITROL net sales towards the high end of our previously announced range of $410 million to $430 million.
Revenue Growth from Proprietary Products: We generated total revenues of $378.1 million driven by our proprietary product portfolio, which grew 18% year-over-year.
Negative
Net Sales Increase: Net sales in the third quarter were $113.7 million compared to $99.3 million in the same period last year, indicating a significant increase but still reflecting challenges in maintaining consistent growth.
ARISTADA Sales Performance: For the ARISTADA product family, net sales were $84.7 million compared to $81.8 million in Q3 last year, showing only marginal growth despite expectations for stronger performance.
Net Sales Increase: LYBALVI generated net sales of $74.7 million, which is a significant increase from $50.7 million for the same period last year, but still indicates volatility in the market.
Decline in INVEGA Revenue: Revenue from long-acting INVEGA products was $58.4 million compared to $76.1 million for Q3 last year, reflecting a decline in sales and market share.
Net Income Challenges: The company reported a GAAP net income from continuing operations of $92.8 million, which is lower than expected, indicating potential challenges in sustaining profitability.
ALKS FAQs
How does ALKS typically perform around its earnings report dates?
Is Alkermes plc (ALKS) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
ALKS Earning Call Sentiment
Alkermes plc (ALKS) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
ALKS.O
2.16%Positive
The earnings call presented strong financial performance with significant growth in key products like LYBALVI and ARISTADA. The share repurchase program and solid cash position further strengthen the company's outlook. Although there were concerns about royalty revenue decline and competitive threats, management's optimistic guidance and strategic focus on growth offset these. The market cap suggests moderate reaction, leading to a positive prediction.
